Gunda I. Georg
Regents Professor and Head Department of Medicinal Chemistry, McKnight Presidential Chair, Robert Vince Endowed Chair
- Chemical Biology
Principal Research Interests
Professor Georg and her group have published more than 230 scientific articles and are involved in the design, semisynthesis, total synthesis, and evaluation of biologically active agents. Current therapeutic areas include cancer, male and female contraception, and epilepsy. These projects require the development of synthetic methods, synthesis of natural products, and structure-activity studies aimed at improving the therapeutic efficacy of lead compounds, including natural products, and hits from high throughput screening. Professor Georg is Editor-in-Chief of the Journal of Medicinal Chemistry published by the American Chemical Society. She is the director of the Institute for Therapeutics Discovery and Development.
Interdisciplinary projects are a main focus in the Georg group, involving medicinal chemistry, biochemistry, pharmacology, pharmaceutical chemistry and reproductive biology. She is the principal investigator of a U54 National Institutes of Health center, Contraceptive Discovery, Development and Behavioral Research Center, which is funded by National Institute of Child Health and Human Development and involves four other universities. Professor Georg is the co-inventor of LusedraTM, which was marketed by Eisa Pharmaceuticals and a co-inventor of Minnelide, an anticancer agent in phase II clinical trials that was developed by an interdisciplinary group at the University of Minnesota.
- Gunda I. Georg, University of Minnesota, Department of Chemistry
- College of Pharmacy (delivery code 1932), 139 Smith Hall, 207 Pleasant St SE
- Minneapolis, MN 55455-0431